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Purpose: To develop an ethylene-vinyl acetate (EVA) matrix system containing a permeation enhancer 
for enhanced transdermal delivery of torasemide.  
Methods: The solubility of torasemide was studied at various volume fraction of polyethylene glycol 
(PEG) 400. The effect of drug concentration was tested at 1.0, 2.0 and 3.0 %, respectively while the 
effect of temperature on drug release from drug-EVA matrix was evaluated at 27, 32, 37 and 42 
o
C. To 
increase pore size and flexibility of the EVA matrix, plasticizers with citrate and phthalate groups were 
added to the matrix containing torasemide. To improve the penetration of torasemide from the EVA 
matrix across the skin, enhancers (propylene glycol derivatives, fatty acids, glycerides, pyrrolidones and 
non-ionic surfactants) were incorporated into the torasemide-EVA matrix. The effects of the enhancers 
on the skin penetration were evaluated using Franz diffusion cell fitted with the intact excised rat skin.  
Results: Solubility and permeation of torasemide was highest at 40 %v/v PEG 400. The release rate of 
drug from drug-EVA matrix increased with increased loading dose and temperature. Release rate was 
proportional to the square root of loading dose. The activation energy (Ea), which was derived from the 
slope of log P versus 1000/T, was 14.95 kcal/mol for 2.0% loading dose. Among the plasticizers used, 
diethyl phthalate showed the highest release rate of torasemide. Among the enhancers used, 
polyoxyethylene 2-oleyl ether showed the greatest enhancing effect.  
Conclusion: For the enhanced controlled transdermal delivery of torasemide, the application of the 
EVA matrix containing plasticizer and penetration enhancer could be useful in the development of a 
transdermal drug delivery system.  
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INTRODUCTION 
 
Torasemide has been used to treat edema 
and primary hypertension and to prevent 
kidney stones [1]. However, it often causes 
many side effects on gastrointestinal system 
such as gastric irritation, nausea, and vomiting 
with repeated oral administration. Therefore, it 
is necessary to consider alternative routes for 
administration of torasemide to avoid these 
adverse effects. Transdermal drug delivery is 
able to avoid the harmful effects due to 
transient high blood concentration of drug 
caused by repeated oral administration and to 
provide sustained drug release for an 
extended period of time from the drug 
reservoir or matrix [2-5]. However, few drugs 
can be administered this way due to the 
barrier function of the skin. The skin is an 
attractive route for drug administration 
because it can avoid the first-pass hepatic 
metabolism of drugs intended for systemic 
action, thereby allowing for potentially lower 
drug doses and reduced side effects. The 
stratum corneum, the outermost layer of the 
skin, is the primary skin barrier, with a 
structure like a brick wall: the corneocytes are 
bricks surrounded by the mortar of the 
intercellular lipid lamellae. The highly 
organized crystalline lipid lamellae play an 
essential role in the barrier properties of the 
stratum corneum. Many techniques can 
disrupt and weaken the highly organized 
intercellular lipids to enhance drug transport 
across the intact skin or to increase the driving 
force for drug permeation.  
 
One of the most controversial methods is the 
use of vesicle formulations as skin delivery 
systems. Penetration enhancers can also 
increase the permeability of the stratum 
corneum [2-5]. Some of the intrinsic 
ingredients in these systems, such as fatty 
acids, phospholipids, and surfactants, 
enhance penetration through the skin, thus 
increasing the absorption of the drug.  
Many new penetration enhancers have been 
developed to improve percutaneous 
absorption of drug. One of these, ethylene-
vinyl acetate (EVA), which is a biocompatible, 
heat-processible, flexible and inexpensive 
material, has been used for transdermal drug 
delivery [3]. In the present study, we therefore 
tested whether an EVA matrix system could 
improve the transdermal delivery of 
torasemide. We performed release studies 
according to loading dose, temperature, and 
plasticizer content. To increase skin 
permeation, we optimized the use of a 
penetration enhancer in the EVA matrix and 
measured drug permeation across rat skin. 
This study was carried out to evaluate the 
possibility of developing the EVA matrix 
system for transdermal delivery of torasemide 
by studying its in vitro release characteristics.  
 




Torasemide was supplied by Roche Korea 
Co., Ltd. Ethylene-vinyl acetate (EVA, 40 % 
vinyl acetate) was purchased from Aldrich 
Chemical Co, Inc (USA). Acetyl tributyl citrate 
(ATBC), tributyl citrate (TBC), acetyl triethyl 
citrate (ATEC) and triethyl citrate (TEC) were 
purchased from Morflex, Inc (USA). Diethyl 
phthalate (DEP) and di-n-butyl phthalate 
(DBP) were from Junsei Chemical Co, Ltd. 
(Japan). Lauric acid, oleic acid and caprylic 
acid were purchased from Tokyo Kasei Kogyo 
Co, Ltd (Japan). 2-Pyrrolidone was purchased 
from Acros Organics (USA). Myristic acid, 
linoleic acid, 1-methyl-2-pyrrolidone, 
polyoxyethylene-2-stearyl ether, 
polyoxyethylene-2-oleyl ether and 
polyoxyethylene-23-lauryl ether were 
purchased from Sigma-Aldrich Co, Ltd (USA). 
Macrogol-6-glycerides, caprylocaproyl 
macrogol-8-glycerides, propylene glycol 
laurate and propylene glycol monolaurate 
were gifts from Gattefose (France). Stearic 
acid and palmitic acid were purchased from 
Kanto Chemical Co, Inc (Japan). Acetonitrile 
and methanol, HPLC grade, were purchased 
from JT Baker, Inc (USA). All the reagents 




Determination of drug solubility 
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Excess amounts of torasemide were 
equilibrated with saline containing various 
concentrations of PEG 400. Each solution was 
shaken at 37 °C for 24 h in shaking incubator. 
The solution was then filtered through 0.45 µm 
membrane filter. The concentration of 
torasemide was determined at 290 nm, after 
appropriate dilution, using a UV 
spectrophotometer (Vectra ES/12, Hewlett 
Packard (U.S.A.). 
 
HPLC determination of torasemide 
 
Torasemide was assayed by high pressure 
liquid chromatography (HPLC) method 
(Waters 484, USA). The HPLC system 
consisted of Degaser (DG-1210, Japan), a 
pump (Knauer, DE/K-120, USA), an injector 
(Alcott, US/708-autosampler, U.S.A.), Restek 
C18 column (250 x 4.6 mm, 5 um), UV detector 
(Waters 484, USA) and an integrator (Youngin 
Scientific Co, Ltd, D520A, Korea). The mobile 
phase was a combination of methanol: distilled 
water (40: 60 v/v) and the column was 
maintained at ambient temperature. A flow 
rate of 1.5 ml/min yielded an operational 
pressure of ~1000 psi. The UV detector was 
operated at a wavelength of 290 nm. Under 
these conditions, the torasemide peak 
appeared at the retention time of 3.647 min.  
 
Preparation of drug-containing EVA matrix  
 
Two grams of EVA copolymer beads was 
dissolved in 20 ml of chloroform in a beaker, 
and drug solution (torasemide-methanol) was 
added. This mixture was poured onto a glass 
plate and the solvent allowed to be evaporated 
at room temperature over a 24-h period. The 
matrix was then removed from the plate.  
 
Release of torasemide from the EVA matrix  
 
The in vitro release of torasemide from the 
EVA matrix was examined in a Franz diffusion 
cell. A unit of EVA matrix was clamped on the 
cell cap, i.e., the upper side of the receptor 
cell. The diameter of the cell cap was 2 cm, 
providing 3.14 cm
2
 effective constant area 
between the matrix and the bulk solution of 21 
ml. PEG 400-water solution (40 %) was used 
as receptor medium. The receptor was 
maintained at 37 °C with a circulating water 
jacket and stirred constantly at 380 rpm. Prior 
to the experiment, the system was tested to 
remove any remaining air bubbles in the 
receptor site. At a predetermined time, the 
whole solution from the receptor cell was 
taken and replaced with fresh solution. The 
cumulative amount of torasemide released 
from the drug-EVA matrix was determined at 
290 nm. 
  
The effect of drug concentration on its release 
from the EVA matrix was studied at the 
following drug concentrations: 1.0, 2.0 and 3.0 
%w/w while the effect of temperature on drug 
release was studied at 27, 32, 37 and 42 °C. 
Each determination was carried out in 
triplicate.  
 
Preparation and of torasemide from drug-
EVA matrix containing the plasticizer 
 
Plasticizers reduce the brittleness, improve 
flow, impart flexibility and increase toughness, 
strength, tear resistance and impact 
resistance of the polymer. Increasing the 
amount of plasticizer could lead to an increase 
in free film elongation and a decrease in 
tensile strength and Young's modulus. Alkyl 
citrates - acetyl tributyl citrate (ATBC), tributyl 
citrate (TBC), acetyl triethyl citrate (ATEC), 
and triethyl citrate (TEC) - and phthalates - 
diethyl phthalate (DEP) and di-n-butyl 
phthalate (DBP) - were used. In each case, 
the plasticizer was dropped into the drug-
containing EVA solution and mixed for 1 h. 
This method was chosen in order to produce 
large defect-free membrane samples with no 
orientation of the molecules. The release of 
torasemide from the EVA matrix containing 
plasticizer was studied at 2.0 % loading dose 
and 37 °C. Each determination was carried out 
in triplicate.  
Enhancement factor (EF) was calculated using 
Eq 1.  
 
EF = Rp/Rc …….. (1)  
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where Rp is the flux of EVA matrix containing 
plasticizer and Rc is the flux of EVA matrix not 
containing plasticizer. . 
 
Skin preparation  
 
A male rat (Sprague Dawley rat strain) was 
sacrificed by excess etherization. The hair was 
carefully removed from the abdominal area 
with an electric clipper. A square section of the 
abdominal skin was then excised, and the 
adhering fat and other visceral debris in the 
skin were carefully removed from the 
undersurface with tweezers [5]. The excised 
abdominal rat skin was used immediately. The 
experiments were carried out in accordance 
with the “Guiding Principles in the Use of 
Animals in Toxicology” adopted by the Society 
of Toxicology (USA) in July 1989 and revised 
in March 1999. The Animal Care Committee of 
Chonnam National University (Gwangju, 
Republic of Korea) approved the study design 
and conduct of this study (ref no. 2009-12). 
 
Preparation of EVA matrix containing an 
enhancer  
 
EVA copolymer beads (2 g) were dissolved in 
20 ml of chloroform in a glass beaker. 
Appropriate amount of drug (40mg) was 
dissolved in 4 ml of methanol and the 
enhancer added. The mixed polymer solution 
was poured onto a glass plate for casting, and 
the solvent was allowed to be evaporated at 
room temperature over a 24-h period. The 
membrane was taken from the plate and dried 
at room temperature. 
 
Permeation of torasemide through rat skin 
from EVA matrix  
 
To improve the penetration of torasemide from 
EVA matrix across skin, various enhancers, 
such as propylene glycol derivatives, fatty 
acids, glycerides, pyrrolidones and non-ionic 
surfactants, were incorporated at 5 % 
concentration into the torasemide-EVA matrix.  
 
The effect of the enhancers on skin 
penetration was evaluated using a Franz 
diffusion cell fitted with excised rat skin. The 
freshly excised full-thickness skin was 
mounted on the receptor site of the diffusion 
cell with the stratum corneum side facing 
upwards, i.e., the donor compartment, and the 
dermal side facing the receptor compartment. 
An appropriate size (2.5 cm) of the matrix was 
placed on the stratum corneum side, covered 
with a round glass plate, and clamped. The 
receptor medium was 40 % PEG 400 solution 
to achieve sink conditions and was maintained 
at 37 °C by a circulating water bath. Test 
samples were withdrawn at predetermined 
time intervals and immediately replaced on 
each occasion with an equal volume of fresh 
medium. Penetrated quantities of torasemide 
were analyzed by HPLC at 290 nm. Each 
determination was carried out in triplicate. The 
enhancement factor (EF) was calculated Eq 2.  
 
EF = Re/Rc …………….………….. (2)  
 
where Re is the flux of EVA matrix containing 





Permeation rate was calculated from the slope 
of the linear region of the permeation profile. 
The flux was calculated from the slope of the 
linear region of the Q versus t permeation 
profile. A linear profile was observed during 
the 16-h experiment and the slope of the linear 
portion of the curve was determined by linear 
regression. Statistical analysis was performed 
using ANOVA, with Student-Newman-Keuls 
employed as a post-hoc test. SigmaStat 
software (version 3.5, Systat software, 
Richmond, CA, USA) was used for all 
analysis. A p-value of less than 0.05 was 
considered statistically significant. All values 





Solubility of torasemide 
 
The solubility of torasemide increased as the 
volume fraction of PEG 400 increased, 
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showing the highest solubility at 40 % PEG 
400 (Fig 1). 
 
PEG 400 (v/v)




















Fig 1: Solubility of torasemide in various PEG 400 
solutions of varying concentration 
 
Effect of drug loading dose on drug release 
 
A characteristic of the drug release profile of 
matrix-type drug delivery system can be 
represented by Higuchi's equation [6]. The 
release from a planar system having 
dispersed drug in a homogeneous matrix 
should follow the relationship in Eq 3.  
 
  Q = [D (2A- Cs) Cs t] 
1/2
 ………………… (3) 
 
where Q is the amount of drug released after 
time, t, per unit exposed area, D is the 
diffusivity of the drug in the matrix, A is the 
initial drug concentration, and C is the drug 
solubility in the matrix. Higuchi later derived 
a similar relationship for planar release from 
a granular matrix system in which diffusion 
occurs through channels, as in Eq 4 [7]:   
 
Q = [D/τ (2A - ε Cs) Cs t] 
1/2
 ……………….. (4) 
where D and Cs refer to diffusivity and 
solubility in the permeability field, 
respectively; τ the tortuosity of the matrix and 
ε the porosity of the matrix. Although the two 
equations are for different mechanisms, they 
both describe drug release as being linear 
with the square root of time, as in Eqs 5 – 7.  
 




where, for the homogeneous matrix system:  
 




and for the granular matrix system: 
 




The validity of the relationships has been 
confirmed experimentally by a number of 
researchers using various systems [8,9]. 
 
The release profile of torasemide from the 
EVA matrix at different drug loads over a 4-h 
period is shown in Fig 2. The cumulative 
amount of torasemide released (Q) versus the 
square root of time (t
1/2
) plot shows good 
linearity for all three concentrations. As 
expected from Equation 9 and 10, a plot of 
Q/t
1/2
 versus the square root of loading dose 
(A) yielded a straight line (Fig 2). Q/t
1/2
 
increased in direct proportion to the increase 
in the loading dose of torasemide. 
 
Effect of medium temperature on drug 
release 
 
The dependency of the drug release profile on 
temperature is shown in Fig 3. The cumulative 
amount of drug released (Q) is plotted versus 
the square root of time (t
1/2
). After an initial 
period of drug release, release became 
approximately linear with respect to t
1/2
. The 
steady-state rate of drug release (Q/t
1/2
) was 
estimated from the slope of the linear Q - t
1/2
 
profile from 0 to 16 h. At higher temperatures, 
drug release Q/t
1/2
 values increased. It should 
be noted that the rate of drug release 
increased about 1.65-fold when the 
temperature of the drug release system was 
raised from 27 to 42 °C. But for practical 
purpose, 37 °C was chosen to reflect the 
temperature of the stratum corneum.  
Permeability coefficient can then be defined by 
Eqs 8 and 9. 
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Fig 2: Relationship between torasemide flux and 
drug loading dose of EVA matrix at 37 °C.  
 
P = Flux/Solubility ……………………….. (8) 
 
P = P0 x e
-Ea/RT
 ……………………………. (9) 
 
Log P = Log P0 -Ea/R/2.303/1000 x 1000/T… (10) 
 
As expected from Equation 8, a plot of log P 
versus 1000/T yielded a straight line (Fig 3).  
 
Slope = -Ea/R/2.303 x 1/1000 …………(11) 
 
Ea = -Slope x R x 2.303 x 1000 cal  = -Slope x 
1.987 x 2.303 kcal …………………… (12) 
 
The Ea (activation energy), which was 
measured from the slope of log P versus 
1000/T plots (Eq 12), was 14.9 kcal/mol for 2.0 
% loading dose in EVA matrix.  
 
Effect of plasticizers on the drug release 
from EVA matrix 
 
In the case of citrate group, there was a slight 
increase in drug release. On the other hand, 
phthalate plasticizers produced a greater 
increase in drug release rate than the citrate 
plasticizers (Table 1). 
1000/T










Fig 3: Effect of temperature on torasemide release 
from EVA matrix containing 2 % loading dose. 
 
Table 1: Effect of plasticizers on torasemide 
release from EVA matrix with 2.0 % loading dose at 
37 
o















Effect of enhancers on the permeation of 
torasemide through rat skin 
 
Table 2 shows the enhancement factor of the 
permeation enhancers on torasemide-EVA 
matrix. The flux of torasemide from the EVA 
matrix containing polyoxyethylene 2-oleyl 
ether (1.59±0.03 ug/cm
2
/hr) was significantly 
increased than in control matrix (0.57±0.01 
ug/cm
2
/h, p < 0.05), as shown in Table 2. 
Amongst all the enhancers used in this study, 
polyoxyethylene-2-oleyl ether showed the 
highest enhancing effect (2.79-fold). 
Cho et al  
Trop J Pharm Res, December 2011;10 (6):  719 
Table 2: Enhancement factor (EF) of various 


















Oleic acid 0.99±0.02 1.74 
Linoleic acid 1.18±0.02 2.07 
Caprylic acid 1.11±0.02 1.95 
Lauric acid 1.25±0.02 2.20 







Propylene glycol mono 
caprylate 
1.17±0.02 2.05 
Propylene glycol laurate 1.22±0.03 2.14 
Propylene glycol mono 
laurate 
1.03±0.02 1.81 
NMP 1.32±0.03 2.32 
2-Pyrrolidone 1.12±0.03 1.96 




Effect of medium temperature on drug 
release 
 
This observation clearly shows that the 
release of torasemide from the EVA matrix is 
an energy-linked process [10]. The increase in 
release with increasing temperature suggests 
that release characteristics of the copolymer 
would change over the body temperature 
range. This finding indicates that special 
precautions should be taken with regard to 
monitoring body temperature in practical 
applications.  
 
Effect of plasticizers on the drug release 
from EVA matrix 
 
Generally, plasticizers increase the amount of 
drug release by increasing the chain mobility 
of the polymer. The plasticizers will interpose 
between the polymer chains and interact with 
the forces to extend and soften the polymer 
matrix [11]. The selection of a suitable 
plasticizer and its concentration has a 
profound influence on the mechanical 
properties as well as on the permeability of 
drugs [11]. Increasing the amount of 
plasticizer could lead to an increase in free 
film elongation and a decrease in tensile 
strength. A strong interaction between a drug 
and a polymer has been reported to 
significantly influence drug release through a 
polymeric film [12].  
 
Effect of enhancers on the permeation of 
torasemide through rat skin 
 
Human skin is an effective, selective barrier to 
chemical permeation [13] and is a strong 
barrier against the penetration of external 
drugs when applied as TDDS. Thus, to 
maximize drug flux, it is usually necessary to 
reduce skin barrier properties, although the 
follicular route may also be important [13]. To 
achieve high permeation rates and attain 
therapeutic dose levels, it is necessary to 
overcome the barrier properties of the stratum 
corneum. Therefore, physical or chemical 
penetration enhancers have become useful 
[14-15].  
 
Compared with control, saturated fatty acid 
group of permeation enhancers only slightly 
increased drug penetration rate. Among this 
group, lauric acid showed the greatest 
increase in penetration rate. Linoleic acid also 
significantly increased the penetration rate of 
the drug from EVA matrix. The saturated fatty 
acid group showed a slightly higher effect on 
penetration rate than the unsaturated fatty 
acid.  
In skin pre-treated with non-ionic surfactant, 
the stratum corneum is loosely layered and 
the intercellular spaces are wide [16]. 
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Polyoxyethylene-2-stearyl ether, polyoxy-
ethylene-23-lauryl ether and polyoxyethyl-
ene-2-oleyl ether produced increased 
penetration rate. In other experiments 
carried out in our laboratory, polyoxy-
ethylene-2-oleyl ether showed the highest 
penetration enhancement effect.   
 
The non-ionic surfactants affect the 
permeability of several biological 
membranes including skin [17] and can thus 
enhance the skin penetration of other 
compounds in the formulation. Therefore, in 
recent years they have been employed to 
enhance the permeation rates of several 
drugs [16-18] and have been studied to 
determine the mechanism of the effect of 
non-ionic surfactants. In skin pre-treated with 
non-ionic surfactant, the stratum corneum 
was loosely layered and the intercellular 
spaces were wide [16]. Polyoxyethylene-2-
stearyl ether, polyoxy-ethylene-23-lauryl 
ether and polyoxy-ethylene-2-oleyl ether 
produced increased penetration rate. 
 
Caprylocaproyl macrogol-8-glyceride increa-
ses the passive transport of drug molecules. It 
shows high tolerance and low toxicity and is 
included as a pharmaceutical excipient in 
European Pharmacopoeia in 2003. Oleyl 
macrogol-6-glyceride is a PEG derivative, 
used as a co-surfactant in pharmaceutical 
systems such as microemulsions. The 
penetration of PGs through the tissue could 
alter the thermodynamic activity of the drugs in 
the vehicle, which would in turn modify the 
driving force for diffusion. PGs may partition 
into the tissue, facilitating uptake of the drug 
into skin, and there may be minor 
disturbances to intercellular lipid packing 
within the stratum corneum bilayers [19]. 
Propylene glycol laurate showed a significant 
penetration rate of torasemide. Within each 
study, significant differences were observed 
among the formulations. 
 
 In terms of the mechanism of action, the 
pyrrolidones partition well into the human 
stratum corneum. Within the tissue, they may 
act by altering the solvent nature of the 
membrane, and pyrrolidones have been used 
to generate 'reservoirs' within skin 
membranes. Such a reservoir effect offers the 
potential for sustained release of a permeant 
from the stratum corneum over an extended 
time period [19].  
 
The flux of torasemide from the EVA matrix 
containing polyoxyethylene 2-oleyl ether 
(1.59±0.03 ug/cm
2
/hr) was significantly 
increased compared with the control group 
(0.57±0.01 ug/cm
2
/hr) (p<0.05) (Table 2). 
Among all enhancers used in this study, 
polyoxyethylene-2-oleyl ether showed the 




Among the plasticizers used, diethyl phthalate 
was the most suitable in terms of 
enhancement torasemide release while 
among the enhancers used, polyoxyethylene-
2-oleyl ether was the most effective in 
enhancing the penetration of torasemide into 
the skin. Thus, for enhanced controlled 
transdermal delivery of torasemide, an EVA 
matrix modulated with suitable plasticizer and 
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